Preliminary trial of poly ICLC in chronic progressive multiple sclerosis

C. T. Bever, A. M. Salazar, E. Neely, B. E. Ferraraccio, J. W. Rose, H. F. McFarland, H. B. Levy, D. E. McFarlin

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Eighteen patients with chronic progressive multiple sclerosis (MS) were treated in an open preliminary trial of the interferon inducer and immune modulator, poly ICLC. All patients produced substantial interferon levels and experienced acute side effects, including fever and transient worsening of neurologic symptoms. Of nine patients with rapid neurologic deterioration at the time of entry into the study, only three had disease progression during treatment. We conclude that poly ICLC can be administered safely to MS patients, and that a controlled trial will be necessary to determine efficacy.

Original languageEnglish (US)
Pages (from-to)494-498
Number of pages5
Issue number4
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Preliminary trial of poly ICLC in chronic progressive multiple sclerosis'. Together they form a unique fingerprint.

Cite this